Return
Company Page
Rejuvenate Bio
Founders
Rejuvenate Bio is a clinical-stage biotechnology company developing novel gene therapies to reverse chronic age-related diseases in both companion animals and humans. Founded on research from George Church's lab at Harvard Medical School and the Wyss Institute, the company leverages liver-directed AAV gene delivery and epigenetic reprogramming to target conditions including heart failure, kidney disease, type 2 diabetes, and obesity. Its capital-efficient model uses the animal health market to generate early revenue and validate therapies ahead of human translation, with a recent strategic R&D collaboration with Merck Animal Health further validating its platform.
Company Founded in 2018
Healthtech & Biotech